Skip to main content

Table 1 Selected novel therapeutics suitable for repositioning for CAD

From: Novel therapeutics for coronary artery disease from genome-wide association study data

Target *Drug name Disease Action Status *Database
CHRM3 Tiotropium Chronic obstructive pulmonary disease Antagonist Approved TTD
HTR1A Fluvoxamine Depressive disorder Unknown Unknown PharmGKB
FLT1 Sorafenib Advanced renal cell carcinoma Inhibitor Launched TTD
ABAT Vigabatrin Epilepsy Inhibitor Approved TTD
GRIK2 Metharbital Epilepsy Antagonist Approved DrugBank
IL2RB Aldesleukin Metastatic renal cell carcinoma Agonist Approved DrugBank
ITGB1 Antithymocyte globulin Prevention of renal transplant rejection Unknown Approved DrugBank
PDGFRA Becaplermin Skin ulcers (from diabetes) Unknown Approved DrugBank
IL2RB Daclizumab Prevention of renal transplant rejection Antibody Approved DrugBank
VEGFA Bevacizumab Metastatic breast cancer Unknown Approved DrugBank
  1. Selected novel therapeutics suitable for repositioning to develop potential treatment of CAD.
  2. (* These drugs mentioned here are only selected examples because one therapeutic target may be associated with multiple drugs); (* Drug databases mentioned here are only selected examples because one drug-target association may be described in more than one drug database). Abbreviations - PH - Phenotype; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase; CAD - Coronary Artery Disease.